US20110091508A1 - Oligofluorinated cross-linked polymers and uses thereof - Google Patents

Oligofluorinated cross-linked polymers and uses thereof Download PDF

Info

Publication number
US20110091508A1
US20110091508A1 US12/681,757 US68175708A US2011091508A1 US 20110091508 A1 US20110091508 A1 US 20110091508A1 US 68175708 A US68175708 A US 68175708A US 2011091508 A1 US2011091508 A1 US 2011091508A1
Authority
US
United States
Prior art keywords
compound
monomer
cross
oligo
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US12/681,757
Other languages
English (en)
Inventor
Roseita Esfand
J. Paul Santerre
Mark J. Ernsting
H. Hung Pham
Vivian Z. Wang
Meilin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interface Biologics Inc
Original Assignee
Interface Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interface Biologics Inc filed Critical Interface Biologics Inc
Priority to US12/681,757 priority Critical patent/US20110091508A1/en
Publication of US20110091508A1 publication Critical patent/US20110091508A1/en
Priority to US15/373,138 priority patent/US10039864B2/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/2805—Compounds having only one group containing active hydrogen
    • C08G18/288—Compounds containing at least one heteroatom other than oxygen or nitrogen
    • C08G18/2885—Compounds containing at least one heteroatom other than oxygen or nitrogen containing halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/48—Polyethers
    • C08G18/4854—Polyethers containing oxyalkylene groups having four carbon atoms in the alkylene group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/67—Unsaturated compounds having active hydrogen
    • C08G18/671—Unsaturated compounds having only one group containing active hydrogen
    • C08G18/672—Esters of acrylic or alkyl acrylic acid having only one group containing active hydrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/77—Polyisocyanates or polyisothiocyanates having heteroatoms in addition to the isocyanate or isothiocyanate nitrogen and oxygen or sulfur
    • C08G18/771—Polyisocyanates or polyisothiocyanates having heteroatoms in addition to the isocyanate or isothiocyanate nitrogen and oxygen or sulfur oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C08G63/912—Polymers modified by chemical after-treatment derived from hydroxycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
    • C08J5/18—Manufacture of films or sheets
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D167/00—Coating compositions based on polyesters obtained by reactions forming a carboxylic ester link in the main chain; Coating compositions based on derivatives of such polymers
    • C09D167/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D167/00—Coating compositions based on polyesters obtained by reactions forming a carboxylic ester link in the main chain; Coating compositions based on derivatives of such polymers
    • C09D167/06—Unsaturated polyesters having carbon-to-carbon unsaturation
    • C09D167/07—Unsaturated polyesters having carbon-to-carbon unsaturation having terminal carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D175/00—Coating compositions based on polyureas or polyurethanes; Coating compositions based on derivatives of such polymers
    • C09D175/04—Polyurethanes
    • C09D175/14—Polyurethanes having carbon-to-carbon unsaturated bonds
    • C09D175/16—Polyurethanes having carbon-to-carbon unsaturated bonds having terminal carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/06—Unsaturated polyesters
    • C08J2367/07—Unsaturated polyesters having terminal carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2371/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
    • C08J2371/02—Polyalkylene oxides

Definitions

  • Fluoropolymers are generally hydrolytically stable and are resistant to destructive chemical environments. In addition they are biocompatible and have been used as components of medical devices. The combination of chemical inertness, low surface energy, antifouling properties, hydrophobicity, thermal and oxidative stability have enabled a great diversity of application for these materials. Fluoropolymers have been prepared from tetrafluoroethylene, via chain growth polymerization reactions, and other fluorinated derivatives, via step growth polymerization reactions producing infinite network fluoropolymers.
  • a challenge for the use of these polymers in certain applications is the processing limitation of working with solid material including, (e.g., fluorinated polyetherurethanes, made from polyether glycols, isocyanates, chain extenders and non-fluorinated polyols) rather than fluids, of which the latter are easily applied into molds or onto surfaces.
  • solid material including, (e.g., fluorinated polyetherurethanes, made from polyether glycols, isocyanates, chain extenders and non-fluorinated polyols) rather than fluids, of which the latter are easily applied into molds or onto surfaces.
  • the problem is even more difficult and almost impossible to manage when the above needs to be cross linked for specific applications.
  • the demand and need for practical fluoropolymers with specific chemical and physical properties has directed the molecular design and development of new fluorinated monomers
  • oligo is an oligomeric segment; each D is a cross-linking domain; and n is an integer from 1 to 20, 1 to 15, 1 to 10, 1 to 8, or even 1 to 5, and wherein at least one D is an oligofluorinated cross-linking domain.
  • oligo is an oligomeric segment; each D is a cross-linking domain; F T is an oligofluoro group; each LinkA-F T is an organic moiety covalently bound to a first oligo, a second oligo, and F T ; n is an integer from 1 to 20; and m is an integer from 1 to 20, wherein at least one D is an oligofluorinated cross-linking domain.
  • Cross-linking domains which can be used in the compositions of the invention include a reactive moiety that capable of chain growth polymerization, such as, without limitation, vinyls, epoxides, aziridines, and oxazolines.
  • the oligofluorinated cross-linking domain is selected from
  • the monomer is further described by formula (III):
  • oligo is an oligomeric segment; vinyl is a cross-linking domain including an unsaturated moiety capable of undergoing radical initiated polymerization; F T is an oligofluoro group covalently tethered to the vinyl and/or the oligo; and each of n, m, and o is, independently, an integer from 1 to 5, wherein the monomer includes at least one oligofluorinated cross-linking domain.
  • the monomer of formula (III) may further be described by formula (IV):
  • oligo is an oligomeric segment; vinyl is a cross-linking domain including an unsaturated moiety capable of undergoing radical initiated polymerization; F T is an oligofluoro group; each LinkA is, independently, an organic moiety covalently bound to oligo, F T , and vinyl; and a, b, and c are integers greater than 0.
  • the monomers of the invention include one or more biologically active agents covalently tethered to the monomer.
  • the invention features a method for coating an article by (a) contacting the article with a monomer of the invention and (b) polymerizing the monomer to form a cross-linked coating.
  • the invention features a method for making a shaped article by (a) polymerizing a monomer of the invention to form a base polymer and (b) shaping the base polymer to form a shaped article.
  • the shaped article is an implantable medical device, such as, without limitation, cardiac-assist devices, catheters, stents, prosthetic implants, artificial sphincters, or drug delivery devices.
  • the shaped article is a nonimplantable medical device.
  • the polymerization step resulting in an oligofluorinated cross-linked polymer of the invention can be initiated, for example, using heat, UV radiation, a photoinitiator, or a free-radical initiator. Desirably, the polymerization is initiated by heat.
  • the step of polymerizing further includes mixing the monomer of the invention with a second compound containing a vinyl group.
  • the second compound can be another monomer of the invention or a nonfluorinated vinyl compound, such as acrylic acid, methyl acrylate, ethyl acrylate, n-butyl acrylate, 2-hydroxyethyl acrylate, n-butyl acrylate, glycidyl acrylate, vinyl acrylate, allyl acrylate, 2-hydroxyethyl acrylate, 2-hydroxy ethyl methacrylate (HEMA), 2-amino ethyl methacrylate, glycerol monomethacrylate, acrylamide, methacrylamide, N-(3-aminopropyl) methacrylamide, crotonamide, allyl alcohol, or 1,1,1-trimethylpropane monoallyl ether.
  • HEMA 2-hydroxyethyl methacrylate
  • the first component includes an oligomeric segment having a first end covalently tethered to a first nucleophilic group and a second end covalently tethered to a second nucleophilic group, wherein the first nucleophilic group or the second nucleophilic group is an oligofluorinated nucleophilic group.
  • the second component includes an oligomeric segment having a first end covalently tethered to a first electrophilic group and a second end covalently tethered to a second electrophilic group, wherein the first electrophilic group or the second electrophilic group is an oligofluorinated electrophilic group.
  • first component or the second component is further described by formula (V):
  • first component or the second component is further described by formula (VI):
  • the nucleophilic groups and the electrophilic groups undergo a nucleophilic substitution reaction, a nucleophilic addition reaction, or both upon mixing.
  • the nucleophilic groups can be selected from, without limitation, primary amines, secondary amines, thiols, alcohols, and phenols.
  • the electrophilic groups can be selected from, without limitation, carboxylic acid esters, acid chloride groups, anhydrides, isocyanato, thioisocyanato, epoxides, activated hydroxyl groups, succinimidyl ester, sulfosuccinimidyl ester, maleimido, and ethenesulfonyl.
  • the number of nucleophilic groups in the mixture is approximately equal to the number of electrophilic groups in the mixture (i.e., the ratio of moles of nucleophilic groups to moles of electrophilic groups is about 2:1 to 1:2, or even about 1:1).
  • the invention also features a method for making a shaped article by (a) polymerizing a composition of the invention to form a base polymer and (b) shaping the base polymer to form a shaped article.
  • X is selected from CH 2 CH 2 —, (CH 2 CH 2 O) n , CH 2 CH(OD)CH 2 O—, CH 2 CH(CH 2 OD)O—, or D-; D is a moiety capable of chain growth polymerization; p is an integer between 2 and 20; and n is an integer between 1 and 10.
  • the vinyl group can be selected, without limitation, from methylacrylate, acrylate, allyl, vinylpyrrolidone, and styrene derivatives.
  • an uncoated implantable medical device can be coated to produce a coated implantable medical device, the coated implantable medical device having, upon implantation into an animal, reduced protein deposition, reduced fibrinogene deposition, reduced platelet deposition, or reduced inflammatory cell adhesion in comparison to the uncoated implantable medical device.
  • base polymer is meant a polymer having a tensile strength of from about 350 to about 10,000 psi, elongation at break from about 5%, 25%, 100%, or 300% to about 1500%, an unsupported thickness of from about 5 to about 100 microns, and a supported thickness of from about 1 to about 100 microns.
  • biologically active agent is meant a compound, be it naturally-occurring or artificially-derived, that is encapsulated in a oligofluorinated cross-linked polymer of the invention and which may be released and delivered to a specific site (e.g., the site at which a medical device is implanted).
  • Biologically active agents may include, for example, peptides, proteins, synthetic organic molecules, naturally occurring organic molecules, nucleic acid molecules, and components thereof.
  • the biologically active agent is a compound useful for the therapeutic treatment of a plant or animal when delivered to a site of diseased tissue.
  • the biologically active agent can be selected to impart non-therapeutic functionality to a surface.
  • Such agents include, for example, pesticides, bactericides, fungicides, fragrances, and dyes.
  • covalently tethered refers to moieties separated by one or more covalent bonds.
  • tethered includes the moieties separated by a single bond as well as both moieties separated by, for example, a LinkA segment to which both moieties are covalently attached.
  • LinkA refers to a coupling segment capable of covalently linking a cross-linking domain, an oligo segment, and an oligofluoro group.
  • LinkA molecules have molecular weights ranging from 40 to 700.
  • the LinkA molecules are selected from the group of functionalized diamines, diisocyanates, disulfonic acids, dicarboxylic acids, diacid chlorides and dialdehydes, wherein the functionalized component has secondary functional chemistry that is accessed for chemical attachment of an oligofluoro group or a vinyl group.
  • Such secondary groups include, for example, esters, carboxylic acid salts, sulfonic acid salts, phosphonic acid salts, thiols, vinyls and secondary amines.
  • Terminal hydroxyls, amines or carboxylic acids on the oligo intermediates can react with diamines to form oligo-amides; react with diisocyanates to form oligo-urethanes, oligo-ureas, oligo-amides; react with disulfonic acids to form oligo-sulfonates, oligo-sulfonamides; react with dicarboxylic acids to form oligo-esters, oligo-amides; react with diacid chlorides to form oligo-esters, oligo-amides; and react with dialdehydes to form oligo-acetal or oligo-imines.
  • LinkA e.g., primary groups of a diamine
  • the LinkA would be, e.g., a hetero functional molecule (such as with an amine and a carboxylic acid as the primary groups) having a primary and a secondary functional chemistry.
  • oligo or “oligo segment” is meant a non-fluorinated relatively short length of a repeating unit or units, generally less than about 50 monomeric units and molecular weights less than 10,000, but preferably ⁇ 5000, and most preferably between 50 and 5,000 Daltons or between 100 and 5,000 Daltons.
  • oligo is selected from the group consisting of polyurethane, polyurea, polyamides, polyalkylene oxide, polycarbonate, polyester, polylactone, polysilicone, polyethersulfone, polyolefin, polyvinyl, polypeptide, polysaccharide; and ether and amine linked segments thereof.
  • the oligo segment is as small as ethylenediamine.
  • oligofluorinated nucleophilic group is meant a nucleophile covalently tethered to an oligofluoro group and separated by fewer than 25, 22, 18, or even 15 covalent bonds.
  • Nucleophiles that can be used in the methods and compositions of the invention include, without limitation, amines, and thiols.
  • oligofluorinated electrophilic group an electrophile covalently tethered to an oligofluoro group and separated by fewer than 25, 22, 18, or even 15 covalent bonds.
  • Electrophiles that can be used in the methods and compositions of the invention include, without limitation, activated acids, epoxy groups, and isocyanates.
  • oligofluorinated cross-linking domain is meant a cross-linking domain covalently tethered to an oligofluoro group and separated by fewer than 25, 22, 18, or even 15 covalent bonds.
  • the oligofluorinated cross-linked polymers of the invention can be formed from a monomer which contains at least one oligofluorinated cross-linking domain.
  • oligofluorinated cross-linked polymer is meant a cross-linked polymer including an oligomeric segment and pendant oligofluoro groups.
  • cross-linking domain is meant a moiety capable of forming covalent linkages via chain growth polymerization reactions.
  • Chain growth polymerization reactions are reactions in which unsaturated monomer molecules add on to a growing polymer chain one at a time, as provided in the following equation:
  • Cross-linking domains can be designed to undergo radical initiated chain polymerization (i.e., in the polymerization of vinyl groups to produce polyvinyl), cationic chain growth polymerization reactions (i.e., cationic ring-opening polymerization, such as in the polymerization of epoxides to produce polyethers, and oxazolines to produce acylated polyamines), and anionic chain growth polymerization reactions (i.e., anionic ring-opening polymerization, such as in the polymerization of epoxides to produce polyethers, and N-methanesulfonyl-2-methylaziridine to produce polyamines).
  • radical initiated chain polymerization i.e., in the polymerization of vinyl groups to produce polyvinyl
  • cationic chain growth polymerization reactions i.e., cationic ring-opening polymerization, such as in the polymerization of epoxides to produce polyethers, and oxazo
  • vinyl monomer an oligo segment covalently tethered to two or more vinyl groups capable of undergoing radical initiated polymerization, wherein at least one vinyl group is contained within an oligofluorinated cross-linking domain.
  • FIG. 1 is an image of a UV cured film of Compound 2, with tensile testing articles punched out, showing Compound 2 processing capability.
  • FIG. 2 is an image of a heat cured film of Compound 2, demonstrating Compound 2 processing capability.
  • FIG. 3 is an image of heat cured shaped articles of Compound 2, showing how an article can be made from Compound 2.
  • FIG. 6 is an image of a heat cured film of Compound 12, demonstrating Compound 12 processing capability.
  • FIG. 8 is an image of a heat cured film of Compound 6 and Compound 8, showing Compound 6 and Compound 8 processing capability.
  • FIG. 10 is an image of a heat cured film of Compound 6 and HEMA, showing Compound 6 processing capability.
  • FIG. 11 is an image of a stent coated with heat cured Compound 2, showing good coverage with minimal webbing.
  • FIG. 12 is an image of an air-deployed stent, coated with heat cured Compound 2, showing good coverage with minimal webbing.
  • FIG. 13 is an image of a stent coated with heat cured Compound 6, demonstrating good coverage with minimal webbing.
  • FIG. 14 is an image of a stent coated with heat cured Compound 6, extracted with toluene, demonstrating the final product properties to remain intact.
  • FIG. 15 is an image of a stent coated with heat cured Compound 6, extracted with buffer, showing the final product properties to remain intact.
  • FIG. 16 is an image of a stent coated with heat cured Compound 8, demonstrating good coverage with minimal webbing.
  • FIG. 17 is an image of a stent coated with heat cured Compound 12 (toluene solvent), showing good coverage with minimal webbing.
  • FIG. 18 is an image of a stent coated with heat cured Compound 12 (toluene:THF solvent), showing good coverage with minimal webbing.
  • FIG. 19 is an image of a stent coated with heat cured Compound 2 and Compound 6, showing good coverage with minimal webbing.
  • FIG. 20 is an image of a stent coated with heat cured Compound 6 and Compound 8, showing good coverage with minimal webbing.
  • FIG. 21 is an image of a stent coated with heat cured Compound 6 and PTX, showing good coverage with minimal webbing.
  • FIG. 22 is a plot of ASA release from a UV cured film of Compound 2 with 10 wt % ASA, showing the release of ASA from Compound 2.
  • FIG. 23 is a plot of ASA release from a UV cured film of Compound 2 with 25 wt % ASA, showing the ability of ASA to be released from Compound 2.
  • FIG. 24 is a plot of ibuprofen release from a heat cured film of Compound 2, demonstrating the ability of ibuprofen to be released from Compound 2.
  • FIG. 25 is a plot of hydrocortisone and dexamethasone release from heat cured films of Compound 6, demonstrating the ability to release drugs from Compound 6.
  • FIG. 26 is an image of a stent coated with heat cured Compound 6 with 1 wt % hydrocortisone, showing good coverage.
  • FIG. 27 is a plot of U937 adhesion to cured films of Compounds 2, 6, 8, and 12, cast on PP, demonstrating a significant reduction in cell adhesion profile.
  • FIG. 28 is is a plot of U937 adhesion to cured films of Compounds 2, 6, 8, and 12, cast on stainless steel, demonstrating a substantial reduction in cell adhesion profile.
  • FIG. 29 is a plot of platelet and fibrinogen interaction with cured films of Compounds 2 and 6, showing a significant reduction in platelet adhesion and fibrinogen adsorption.
  • the invention features oligofluorinated cross-linked polymers. Once cured, the oligofluorinated cross-linked polymer is useful as a base polymer in the manufacture of articles or as an oligofluorinated coating. In certain embodiments, the oligofluorinated cross-linked polymer is formed from a combination of both chain growth and step growth polymerization reactions.
  • the coatings of the invention can also be used to encapsulate therapeutic agents.
  • the oligofluorinated cross-linked polymers of the invention can be produced via chain growth polymerization reactions, nucleophilic substitution reactions, and/or a nucleophilic addition reactions. Regardless of how the oligofluorinated cross-linked polymer is produced, the resulting polymer will include pendant oligofluoro groups, an oligomeric segment, and, optionally, LinkA groups (used to covalently tether the various components together).
  • the quality and performance of the oligofluorinated cross-linked polymers can be varied depending upon the chemical composition and cured characteristics of polymerization step. Desirably, the precursor monomers materials exhibit high reactivity, resulting in efficient curing and fast curing kinetics.
  • the oligofluorinated cross-linked polymers of the invention can be designed to result in a wide variety of desired mechanical properties, release profiles (where a biologically active agent is incorporated), and reduced protein and cell interactions (e.g., when used for in vivo applications). In part, this task entails and defines the formation of a three dimensional network.
  • the properties can vary with chemical composition of the oligofluorinated precursor (e.g., altering the oligo segment or the positioning of the cross linking domain within) and with the polymerization conditions (e.g., by the inclusion of additives, or altering the concentration of the oligofluorinated precursor, to alter the cross-linking density).
  • chemical composition of the oligofluorinated precursor e.g., altering the oligo segment or the positioning of the cross linking domain within
  • the polymerization conditions e.g., by the inclusion of additives, or altering the concentration of the oligofluorinated precursor, to alter the cross-linking density.
  • the extent to which the properties of the oligofluorinated cross-linked polymer can be controlled is one of the advantages of the invention.
  • the monomers of the invention include at least one oligofluoro group.
  • the oligofluoro group (F T ) has a molecular weight ranging from 100 to 1,500 and is incorporated into the oligomers of the invention by reaction of the corresponding perfluoroalkyl group with LinkA moiety.
  • F T is selected from a group consisting of radicals of the general formula: CF 3 (CF 2 ) p CH 2 CH 2 , (CF 3 ) 2 CF(CF 2 ) p CH 2 CH 2 , or (CF 3 ) 3 C(CF 2 ) p CH 2 CH 2 , wherein p is 2-20, preferably 2-8, and CF 3 (CF 2 ) m (CH 2 CH 2 O) n , (CF 3 ) 2 CF(CF 2 ) m (CH 2 CH 2 O) n , or (CF 3 ) 3 C(CF 2 ) m (CH 2 CH 2 O) n , wherein n is 1-10 and m is 1-20, preferably 1-8.
  • F T can be incorporated into a monomer by reaction of an oligofluorinated alcohol with LinkA or an oligo segment.
  • F T typically includes a single fluoro-tail, but are not limited to this feature.
  • a general formula for the oligomeric fluoro-alcohol of use in the invention is H—(OCH 2 CH 2 ) n —(CF 2 ) m —CF 3 , wherein n can range from 1 to 10, but preferably ranges from 1 to 4, and m can range from 1 to 20, but preferably ranges from 1-8.
  • n should be equal to or greater than 2n in order to minimize the likelihood of the (OCH 2 CH 2 ) n segment displacing the (CF 2 ) m —CF 3 from the surface following exposure to water, since the former is more hydrophilic than the fluoro-tail and will compete with the fluoro-tail for surface dominance in the polymerized form.
  • the presence of the (OCH 2 CH 2 ) n segment is believed to have an important function within the oligofluoro domain, as it provides a highly mobile spacer segment between the fluoro-tail and the substrate. This spacer effectively exposes the oligofluorinated surface to, for example, an aqueous medium.
  • oligofluoro groups that incorporate reactive moieties for undergoing cross-linking are provided in Table 1.
  • the examples provided include vinyl groups for undergoing chain growth polymerizations.
  • Similar oligofluoro groups incorporating nucleophiles or electrophiles can be prepared for use in the preparation of oligofluorinated cross-linked polymers made via nucleophilic substitution reactions, and/or a nucleophilic addition reactions.
  • the monomers of the invention include at least one oligomeric segment.
  • the oligo segment is covalently tethered to two or more cross-linking domains and at least one oligofluoro group.
  • Oligo segments can include, for example, polytetramethylene oxide, polycarbonate, polysiloxane, polypropylene oxide, polyethylene oxide, polyamide, polysaccharide, or any other oligomeric chain.
  • the oligo segment can include two or more hydroxyls, thiols, carboxylic acids, diacid chlorides or amides for coupling with LinkA, a cross-linking domain, and/or an oligofluoro group.
  • Useful oligo segments include, without limitation, linear diamine or diol derivatives of polycarbonate, polysiloxanes, polydimethylsiloxanes; polyethylene-butylene co-polymers; polybutadienes; polyesters; polyurethane/sulfone co-polymers; polyurethanes, polyamides including oligopeptides (polyalanine, polyglycine or copolymers of amino-acids) and polyureas; polyalkylene oxides and specifically polypropylene oxide, polyethylene oxide and polytetramethylene oxide.
  • the average molecular weight of the oligo segment can vary from 50 to 5,000 or 100 to 5,000, but in certain embodiments is less than 2,500 Daltons. Oligomeric components can be relatively short in length in terms of the repeating unit or units, and are generally less than 20 monomeric units.
  • the monomers of the invention optionally include one or more LinkA groups.
  • LinkA groups have molecular weights ranging from 40 to 700 Da and have multiple functionality in order to permit coupling of oligo segments, F T , and/or cross-linking domains.
  • Examples of LinkA groups include, without limitation, lysine diisocyanato esters (e.g., lysine diisocyanato methyl ester); 2,5-diaminobenzenesulfonic acid; 4,4′diamino 2,2′-biphenyl disulfonic acid; 1,3-diamino 2-hydroxypropane; and N-(2-aminoethyl)-3-aminopropane sulfonate.
  • lysine diisocyanato esters e.g., lysine diisocyanato methyl ester
  • 2,5-diaminobenzenesulfonic acid 4,4′diamino 2,2′
  • Cross-linking domains can be selected from a variety of different moieties which can undergo chain growth polymerizations.
  • cross-linking domains can be designed to undergo radical initiated chain polymerization (i.e., in the polymerization of vinyl groups to produce polyvinyl), cationic chain growth polymerization reactions (i.e., cationic ring-opening polymerization, such as in the polymerization of epoxides to produce polyethers, and oxazolines to produce acylated polyamines), and anionic chain growth polymerization reactions (i.e., anionic ring-opening polymerization, such as in the polymerization of epoxides to produce polyethers, and N-methanesulfonyl-2-methylaziridine to produce polyamines).
  • radical initiated chain polymerization i.e., in the polymerization of vinyl groups to produce polyvinyl
  • cationic chain growth polymerization reactions i.e., cationic ring-open
  • the oligofluorinated cross-linked polymers of the invention can be formed from a monomer which contains at least one oligofluorinated cross-linking domain.
  • such monomers can include at least one pendant oligofluoro chain (F T ) located adjacent to a step growth resultant functional group (urethane, urea, amide, ester, etc.) within LinkA, or an oligo segment, and at least two unreacted pendant cross-linking domains.
  • the cross-linking domains and F T can be covalently tethered to a non-fluorinated oligo segment via LinkA, or F T can be directly tethered to a cross-linking domain and, together, covalently linked to the oligo segment via LinkA.
  • Both LinkA and the oligo segment may designed to provide for a defined spatial distribution of F T groups, where more than one F T group is present in the monomer. This distribution simultaneously serves as a defining parameter, dictating the modulus, protein and cell interactions, and biochemical stability of the final polymer.
  • the monomer of the invention includes at least two vinyl groups.
  • the vinyl groups are derivatized to include at least one functional group (e.g., a carboxylic acid, hydroxyl, amine, or thiol group), which is used to covalently tether the vinyl group to a biologically active agent, LinkA, and/or oligo.
  • Vinyl groups useful in the methods and compositions of the invention include, without limitation, methacrylate, acrylate, cyclic or linear vinyl moieties, and allyl and styrene containing moieties, and typically have molecular weights ranging from 40 to 2000.
  • composition contains at least two components having reactive groups thereon, with the functional groups selected so as to enable reaction between the components, i.e., crosslinking to form an oligofluorinated cross-linked polymer.
  • Each component has a core substituted with reactive groups.
  • the composition will contain a first component having a core substituted with nucleophilic groups and a second component having a core substituted with electrophilic groups.
  • the composition includes at least one oligofluorinated nucleophilic group or at least one oligofluorinated electrophilic group.
  • each of the first and second components there is preferably plurality of reactive groups present in each of the first and second components.
  • one component may have a core substituted with m nucleophilic groups, where m ⁇ 2, and the other component has a core substituted with n electrophilic groups, where n ⁇ 2 and m+n>4.
  • the reactive groups are electrophilic and nucleophilic groups, which undergo a nucleophilic substitution reaction, a nucleophilic addition reaction, or both.
  • electrophilic refers to a reactive group that is susceptible to nucleophilic attack, i.e., susceptible to reaction with an incoming nucleophilic group.
  • Electrophilic groups herein are positively charged or electron-deficient, typically electron-deficient.
  • nucleophilic refers to a reactive group that is electron rich, has an unshared pair of electrons acting as a reactive site, and reacts with a positively charged or electron-deficient site.
  • nucleophilic groups suitable for use in the invention include, without limitation, primary amines, secondary amines, thiols, phenols, and alcohols. Certain nucleophilic groups must be activated with a base so as to be capable of reaction with an electrophilic group. For example, when there are nucleophilic sulfhydryl and hydroxyl groups in the multifunctional compound, the compound must be admixed with an aqueous base in order to remove a proton and provide a thiolate or hydroxylate anion to enable reaction with the electrophilic group. Unless it is desirable for the base to participate in the reaction, a non-nucleophilic base is preferred. In some embodiments, the base may be present as a component of a buffer solution.
  • electrophilic groups provided on the multifunctional compound must be made so that reaction is possible with the specific nucleophilic groups.
  • the Y groups are selected so as to react with amino groups.
  • the X reactive groups are sulfhydryl moieties
  • the corresponding electrophilic groups are sulfhydryl-reactive groups, and the like.
  • electrophilic groups suitable for use in the invention include, without limitation, carboxylic acid esters, acid chloride groups, anhydrides, isocyanato, thioisocyanato, epoxides, activated hydroxyl groups, succinimidyl ester, sulfosuccinimidyl ester, maleimido, and ethenesulfonyl.
  • Carboxylic acid groups typically must be activated so as to be reactive with a nucleophile.
  • Activation may be accomplished in a variety of ways, but often involves reaction with a suitable hydroxyl-containing compound in the presence of a dehydrating agent such as dicyclohexylcarbodiimide (DCC) or dicyclohexylurea (DHU).
  • a dehydrating agent such as dicyclohexylcarbodiimide (DCC) or dicyclohexylurea (DHU).
  • DCC dicyclohexylcarbodiimide
  • DHU dicyclohexylurea
  • a carboxylic acid can be reacted with an alkoxy-substituted N-hydroxy-succinimide or N-hydroxysulfosuccinimide in the presence of DCC to form reactive electrophilic groups, the N-hydroxysuccinimide ester and the N-hydroxysulfosuccinimide ester, respectively.
  • Carboxylic acids may also be activated by reaction with an acyl halide such as an acyl chloride (e.g., acetyl chloride), to provide a reactive anhydride group.
  • an acyl halide such as an acyl chloride (e.g., acetyl chloride)
  • a carboxylic acid may be converted to an acid chloride group using, e.g., thionyl chloride or an acyl chloride capable of an exchange reaction.
  • the concentration of each of the components will be in the range of about 1 to 50 wt %, generally about 2 to 40 wt %.
  • the preferred concentration will depend on a number of factors, including the type of component (i.e., type of molecular core and reactive groups), its molecular weight, and the end use of the resulting three-dimensional matrix. For example, use of higher concentrations of the components, or using highly functionalized components, will result in the formation of a more tightly crosslinked network, producing a stiffer, more robust composition, such as for example a gel.
  • the mechanical properties of the three-dimensional matrix should be similar to the mechanical properties of the surface to which the matrix (or matrix-forming components) will be applied.
  • the gel matrix when the matrix will be used for an orthopedic application, the gel matrix should be relatively firm, e.g., a firm gel; however, when the matrix will be used on soft tissue, as for example in tissue augmentation, the gel matrix should be relatively soft, e.g., a soft gel.
  • Substrates which can be coated using the methods and compositions of the invention include, without limitation, wood, metals, ceramics, plastics, stainless steels, fibers, and glasses, among others.
  • oligofluorinated cross-linked polymers of the invention are synthesized from monomers which can be prepared, for example, as described in Schemes 1-4 below.
  • oligo is an oligomeric segment
  • LinkA is a linking element as defined herein
  • Bio is a biologically active agent
  • F T is an oligofluoro group
  • D is a moiety capable of undergoing a chain growth polymerization reaction, nucleophilic substitution reaction, and/or a nucleophilic addition reaction.
  • the monomers can be synthesized, for example, using multi-functional LinkA groups, a multi-functional oligo segment, a mono-functional F T group, and cross-linking domains having at least one functional component that can be covalently tethered to the oligomeric segment.
  • the first step of the synthesis can be carried out by classical urethane/urea reactions using the desired combination of reagents. However, the order in which the various components are assembled can be varied for any particular monomer.
  • the oligofluorinated cross-linked polymers of the invention can be used to form coatings which provide for the discrete distribution of mono-dispersed oligofluoro groups in a pendant arrangement on a surface that is stable (e.g., does not readily leach from the surface).
  • the coatings of the invention can be formed by polymerization of an oligofluorinated cross-linking domain, such as a vinyl monomer, or by reaction of a multifunctional nucleophile with an oligofluorinated electrophile or a multifunctional electrophile with an oligofluorinated nucleophile.
  • an oligofluorinated cross-linking domain such as a vinyl monomer
  • the coatings of the invention can impart high water repellency, low refractive index, soil resistance, reduce fouling, and improve biocompatibility.
  • the coatings can reduce the formation of blood clots at the device surface after implantation.
  • the monomer can be applied to a surface alone (e.g., as a liquid); in the presence of a diluent (e.g., acetone, methanol, ethanol, ethers, hexane, toluene, or tetrahydrofuran), in combination with an oligofluorinated precursor.
  • a diluent e.g., acetone, methanol, ethanol, ethers, hexane, toluene, or tetrahydrofuran
  • Suitable methods for applying the monomer to a surface include, without limitation, spin coating, spraying, roll coating, dipping, brushing, and knife coating, among others.
  • Polymerization of the monomers of the invention can be achieved by UV radiation, electron beam, or thermal heat in the presence of a photoinitiator or free-radical thermal initiator, depending upon the nature of the reactive moiety employed.
  • a typical source is ultraviolet (UV) radiation.
  • a typical UV lamp is a lamp equipped with a lamp output of 400 W/in (purchased from Honle UV America Inc.). The lamp is secured on top of a home-built box (26.5 cm length, 26.5 cm width and 23.0 cm height). The box is designed to control the curing environment, using either an air or nitrogen atmosphere.
  • a wide variety of articles can be coated using the compositions and methods of the invention.
  • articles which contact bodily fluids such as medical devices can be coated to improve their biocompatibility.
  • the medical devices include, without limitation, catheters, guide wires, vascular stents, micro-particles, electronic leads, probes, sensors, drug depots, transdermal patches, vascular patches, blood bags, and tubing.
  • the medical device can be an implanted device, percutaneous device, or cutaneous device.
  • Implanted devices include articles that are fully implanted in a patient, i.e., are completely internal.
  • Percutaneous devices include items that penetrate the skin, thereby extending from outside the body into the body. Cutaneous devices are used superficially.
  • Implanted devices include, without limitation, prostheses such as pacemakers, electrical leads such as pacing leads, defibrillarors, artificial hearts, ventricular assist devices, anatomical reconstruction prostheses such as breast implants, artificial heart valves, heart valve stents, pericardial patches, surgical patches, coronary stents, vascular grafts, vascular and structural stents, vascular or cardiovascular shunts, biological conduits, pledges, sutures, annuloplasty rings, stents, staples, valved grafts, dermal grafts for wound healing, orthopedic spinal implants, orthopedic pins, intrauterine devices, urinary stents, maxial facial reconstruction plating, dental implants, intraocular lenses, clips, sternal wires, bone, skin, ligaments, tendons, and combination thereof.
  • prostheses such as pacemakers, electrical leads such as pacing leads, defibrillarors, artificial hearts, ventricular assist devices, anatomical reconstruction prostheses such as breast implants, artificial
  • Percutaneous devices include, without limitation, catheters or various types, cannulas, drainage tubes such as chest tubes, surgical instruments such as forceps, retractors, needles, and gloves, and catheter cuffs.
  • Cutaneous devices include, without limitation, burn dressings, wound dressings and dental hardware, such as bridge supports and bracing components.
  • Stents are commonly used for the treatment of stenosis.
  • stent is crimped onto a balloon catheter, inserted in the coronary vessel of blockage and the balloon is inflated causing the stent to expand to a desired diameter hence opening up the blocked artery vessel for blood flow.
  • Stent coating offers a platform for the delivery of biologically active agents for controling post deployment restenosis.
  • drug delivery on the stent is achieved by formulating a solution with a polymer dissolved in a solvent, and a biologically active agent dispersed in the blend.
  • the solvent is allowed to evaporate, leaving on the stent surface the polymer with the drug embedded in the polymer matrix.
  • the biologically active agent is covalently bound to the oligofluorinated precursor prior to polymerization.
  • the release of the biologically active agent covalently bound to the resulting oligofluorinated cross-linked polymer can be controlled by utilizing a degradable linker (e.g., a ester linkage) to attach the biologically active agent.
  • a degradable linker e.g., a ester linkage
  • the coatings of the invention can be applied to wood for exterior applications (decks and fences), boats, ships, fabrics, electronic displays, gloves, and apparel.
  • intercalative oligofluorinated cross-linked polymer is the ability to initiate the polymerization step on the device surface, producing a continuous polymer coating similar to skin wrap.
  • Articles can be formed from the oligofluorinated cross-linked polymers of the invention.
  • the oligofluorinated precursor can be combined with an initiator using reaction injection molding to produce a shaped article.
  • any shaped article can be made using the compositions of the invention.
  • articles suitable for contact with bodily fluids such as medical devices can be made using the compositions described herein.
  • the duration of contact may be short, for example, as with surgical instruments or long term use articles such as implants.
  • the medical devices include, without limitation, catheters, guide wires, vascular stents, micro-particles, electronic leads, probes, sensors, drug depots, transdermal patches, vascular patches, blood bags, and tubing.
  • the medical device can be an implanted device, percutaneous device, or cutaneous device.
  • Implanted devices include articles that are fully implanted in a patient, i.e., are completely internal.
  • Percutaneous devices include items that penetrate the skin, thereby extending from outside the body into the body.
  • Implanted devices include, without limitation, prostheses such as pacemakers, electrical leads such as pacing leads, defibrillarors, artificial hearts, ventricular assist devices, anatomical reconstruction prostheses such as breast implants, artificial heart valves, heart valve stents, pericardial patches, surgical patches, coronary stents, vascular grafts, vascular and structural stents, vascular or cardiovascular shunts, biological conduits, pledges, sutures, annuloplasty rings, stents, staples, valved grafts, dermal grafts for wound healing, orthopedic spinal implants, orthopedic pins, intrauterine devices, urinary stents, maxial facial reconstruction plating, dental implants, intraocular lenses, clips, sternal wires, bone, skin, ligaments, tendons, and combination thereof.
  • prostheses such as pacemakers, electrical leads such as pacing leads, defibrillarors, artificial hearts, ventricular assist devices, anatomical reconstruction prostheses such as breast implants, artificial
  • Percutaneous devices include, without limitation, catheters or various types, cannulas, drainage tubes such as chest tubes, surgical instruments such as forceps, retractors, needles, and gloves, and catheter cuffs.
  • Cutaneous devices include, without limitation, burn dressings, wound dressings and dental hardware, such as bridge supports and bracing components.
  • Biologically active agents can be encapsulated within the coatings and articles of the invention.
  • the encapsulation can be achieved either by coating the article to be treated with a biologically active agent prior to application and polymerization of the monomer, or by mixing the monomer and the biologically active agent together and applying the mixture to the surface of the article prior to polymerization.
  • Biologically active agents include therapeutic, diagnostic, and prophylactic agents. They can be naturally occurring compounds, synthetic organic compounds, or inorganic compounds.
  • Biologically active agents that can be used in the methods and compositions of the invention include, but are not limited to, proteins, peptides, carbohydrates, antibiotics, antiproliferative agents, rapamycin macrolides, analgesics, anesthetics, antiangiogenic agents, vasoactive agents, anticoagulants, immunomodulators, cytotoxic agents, antiviral agents, antithrombotic drugs, such as terbrogrel and ramatroban, antibodies, neurotransmitters, psychoactive drugs, oligonucleotides, proteins, lipids, and any biologically active agent described herein.
  • Exemplary therapeutic agents include growth hormone, for example human growth hormone, calcitonin, granulocyte macrophage colony stimulating factor (GMCSF), ciliary neurotrophic factor, and parathyroid hormone.
  • Other specific therapeutic agents include parathyroid hormone-related peptide, somatostatin, testosterone, progesterone, estradiol, nicotine, fentanyl, norethisterone, clonidine, scopolomine, salicylate, salmeterol, formeterol, albeterol, valium, heparin, dermatan, ferrochrome A, erythropoetins, diethylstilbestrol, lupron, estrogen estradiol, androgen halotestin, 6-thioguanine, 6-mercaptopurine, zolodex, taxol, lisinopril/zestril, streptokinase, aminobutytric acid, hemostatic aminocaproic acid, parlodel, tacrine
  • the biologically active agent can be an antiinflammatory agent, such as an NSAID, corticosteriod, or COX-2 inhibitor, e.g., rofecoxib, celecoxib, valdecoxib, or lumiracoxib.
  • an NSAID such as an NSAID, corticosteriod, or COX-2 inhibitor, e.g., rofecoxib, celecoxib, valdecoxib, or lumiracoxib.
  • Exemplary diagnostic agents include imaging agents, such as those that are used in positron emission tomography (PET), computer assisted tomography (CAT), single photon emission computerized tomography, X-ray, fluoroscopy, and magnetic resonance imaging (MRI).
  • imaging agents such as those that are used in positron emission tomography (PET), computer assisted tomography (CAT), single photon emission computerized tomography, X-ray, fluoroscopy, and magnetic resonance imaging (MRI).
  • Suitable materials for use as contrast agents in MRI include gadolinium chelates, as well as iron, magnesium, manganese, copper, and chromium chelates.
  • Examples of materials useful for CAT and X-rays include iodine based materials.
  • a preferred biologically active agent is a substantially purified peptide or protein.
  • Proteins are generally defined as consisting of 100 amino acid residues or more; peptides are less than 100 amino acid residues. Unless otherwise stated, the term protein, as used herein, refers to both proteins and peptides.
  • the proteins may be produced, for example, by isolation from natural sources, recombinantly, or through peptide synthesis. Examples include growth hormones, such as human growth hormone and bovine growth hormone; enzymes, such as DNase, proteases, urate oxidase, alronidase, alpha galactosidase, and alpha glucosidase; antibodies, such as trastuzumab.
  • Rapamycin is an immunosuppressive lactam macrolide that is produced by Streptomyces hygroscopicus. See, for example, McAlpine, J. B., et al., J. Antibiotics 44: 688 (1991); Schreiber, S. L., et al., J. Am. Chem. Soc. 113: 7433 (1991); and U.S. Pat. No. 3,929,992, incorporated herein by reference.
  • Exemplary rapamycin macrolides which can be used in the methods and compositions of the invention include, without limitation, rapamycin, CCI-779, Everolimus (also known as RAD001), and ABT-578.
  • CCI-779 is an ester of rapamycin (42-ester with 3-hydroxy-2-hydroxymethyl-2-methylpropionic acid), disclosed in U.S. Pat. No. 5,362,718.
  • Everolimus is an alkylated rapamycin (40-O-(2-hydroxyethyl)-rapamycin, disclosed in U.S. Pat. No. 5,665,772.
  • antiproliferative agents which can be used in the methods and compositions of the invention include, without limitation, mechlorethamine, cyclophosphamide, iosfamide, melphalan, chlorambucil, uracil mustard, estramustine, mitomycin C, AZQ, thiotepa, busulfan, hepsulfam, carmustine, lomustine, semustine, streptozocin, dacarbazine, cisplatin, carboplatin, procarbazine, methotrexate, trimetrexate, fluouracil, floxuridine, cytarabine, fludarabine, capecitabine, azacitidine, thioguanine, mercaptopurine, allopurine, cladribine, gemcitabine, pentostatin, vinblastine, vincristine, etoposide, teniposide, topotecan, irinotecan, camptostat
  • corticosteroids which can be used in the methods and compositions of the invention include, without limitation, 21-acetoxypregnenolone, alclomerasone, algestone, amcinonide, beclomethasone, betamethasone, betamethasone valerate, budesonide, chloroprednisone, clobetasol, clobetasol propionate, clobetasone, clobetasone butyrate, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacon, desonide, desoximerasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flumethasone pivalate, flunisolide, flucinolone acetonide, fluocinonide, fluorocino
  • NSAIDs non-steroidal antiinflammatory drugs
  • NSAIDs non-steroidal antiinflammatory drugs
  • analgesics which can be used in the methods and compositions of the invention include, without limitation, morphine, codeine, heroin, ethylmorphine, O-carboxymethylmorphine, O-acetylmorphine, hydrocodone, hydromorphone, oxymorphone, oxycodone, dihydrocodeine, thebaine, metopon, ethorphine, acetorphine, diprenorphine, buprenorphine, phenomorphan, levorphanol, ethoheptazine, ketobemidone, dihydroetorphine and dihydroacetorphine.
  • antimicrobials which can be used in the methods and compositions of the invention include, without limitation, penicillin G, penicillin V, methicillin, oxacillin, cloxacillin, dicloxacillin, nafcillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, azlocillin, temocillin, cepalothin, cephapirin, cephradine, cephaloridine, cefazolin, cefamandole, cefuroxime, cephalexin, cefprozil, cefaclor, loracarbef, cefoxitin, cefmatozole, cefotaxime, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, cefixime, cefpodoxime, ceftibuten, cefdinir, cefpirome, cefepime, BAL5788, B
  • Exemplary local anesthetics which can be used in the methods and compositions of the invention include, without limitation, cocaine, procaine, lidocaine, prilocaine, mepivicaine, bupivicaine, articaine, tetracaine, chloroprocaine, etidocaine, and ropavacaine.
  • antispasmodics which can be used in the methods and compositions of the invention include, without limitation, atropine, belladonna, bentyl, cystospaz, detrol (tolterodine), dicyclomine, ditropan, donnatol, donnazyme, fasudil, flexeril, glycopyrrolate, homatropine, hyoscyamine, levsin, levsinex, librax, malcotran, novartin, oxyphencyclimine, oxybutynin, pamine, tolterodine, tiquizium, prozapine, and pinaverium.
  • SCX-SPE Cationic Solid Phase Extraction
  • Fluorous Solid Phase Extraction SPE substrates modified with perfluorinated ligands (F-SPE) are used to selectively retain perfluorinated oligomers, allowing the separation of non-fluorinated compounds.
  • Elemental analysis samples are combusted, and the liberated fluorine is absorbed into water and analyzed by ion-selective electrode.
  • FTIR analysis a sample is dissolved as a 20 mg/mL solution in a suitable volatile solvent and 50 ⁇ L of this solution is cast on a KBr disk. Once dried, the sample is analyzed.
  • Gel extraction samples of film are weighed and then extracted with a suitable solvent for 12 hours. The films are removed from the solvent, weighed, and then vacuum dried and weighed again. Gel content is calculated as the percentage of mass that is not extracted. Swell ratio is calculated at the percentage increase in mass before the sample is vacuum dried.
  • GPC analysis samples are dissolved as a 20 mg/mL solution in a suitable solvent (THF, dioxane, DMF) and are analyzed using a polystyrene column calibrated with polystyrene standards.
  • a suitable solvent THF, dioxane, DMF
  • XPS analysis films are analyzed using a 90° take-off angle.
  • Polytetramethylene oxide (PTMO) (15 grams, 14 mmol) was weighed into a 500 mL 2-neck flask and degassed overnight at 30° C., and was then dissolved in anhydrous DMAc (40 mL) under N 2 .
  • LDI 5.894 g, 28 mmol was weighed into a 2-neck flask and was dissolved in anhydrous DMAc (40 mL) under N 2 .
  • DBDL was added to the LDI solution, and this mixture was added dropwise to the PTMO solution. The flask was kept sealed and maintained under N 2 at 70° C. for two hours.
  • Fluoroalcohol 13.151 g, 31 mmol was weighed into a 2-neck flask and degassed at room temperature, was dissolved in anhydrous DMAc (40 mL) and was added dropwise to the reaction mixture. The reaction solution was sealed under N 2 and was stirred overnight at room temperature. The product was precipitated in water (3 L), washed several times, and dried. The product was dissolved in MeOH and the tin catalyst was extracted by SCX SPE. The final product (Compound 1-ester) was dried under vacuum.
  • the washed product was dissolved in diethyl ether (100 mL, 100 ppm BHT), and water was removed by mixing the solution with MgSO 4 for 1 hour.
  • the solution was clarified by gravity filtration into a 250 mL flask, and the solvent was removed by rotary evaporation (25° C.).
  • the product (Compound 2) was re-dissolved in DMF and was purified by fluorous SPE (F-SPE) and recovered by rotary evaporation.
  • IR analysis was in accordance with the chemical structure: 3318 cm ⁇ 1 v(N—H) H-bonded, 2935 cm ⁇ 1 v(C—H) CH 2 asymmetric stretching, 2854 cm ⁇ 1 v(C—H) CH 2 symmetric stretching, 1722 cm ⁇ 1 v(C ⁇ O) urethane amide, 1634 cm ⁇ 1 (vinyl C ⁇ C stretching), 1532 cm ⁇ 1 v(C—N) stretching mode, 1456 cm ⁇ 1 v(C—N) stretching mode, 1349.31 cm ⁇ 1 v(C—O) stretching, 1400-1000 cm ⁇ 1 v(C—F) monofluoroalkanes absorb to the right in the range, while polyfluoroalkanes give multiple strong bands over the range from 1350-1100 cm ⁇ 1 .
  • Elemental analysis theoretical based on reagent stoichiometry (%): C, 49.64; H, 6.53; F, 21.71; N, 2.56; O, 19.55. Measured: C, 50.78; H, 6.89; F, 19.33; N, 2.50.
  • the amount of allyl alcohol attached onto the oligomer after the reaction was estimated to be 72%.
  • the absolute number-average molecular weight (Mn) was estimated, using pentafluorobenzene (6.90 ppm) as the external reference against BAL at 2.46 ppm, PTMO at 3.42 ppm, LDI at 3.15 ppm and allyl at 5.92 ppm, to be 1845 g/mol.
  • Compound 4 was prepared by conjugating fluorinated groups to Compound 13 from Example 11.
  • the amount of BAL attached onto the oligomer after the reaction was estimated to be 67%.
  • the absolute number-average molecular weight (Mn) was estimated, using pentafluorobenzene (6.90 ppm) as the external reference against allyl at 5.92 ppm, PTMO at 3.42 ppm, BAL at 2.50 ppm and LDI at 3.17 ppm, to be 2007 g/mol.
  • FTIR (KBr, neat): 3315 (N—H, broad), 2933-2794 (aliphatic C—H), 1720 (C ⁇ O), 1644 (C ⁇ C), 1530, 1436, 1365, 1247, 1110, 778, 742, 733, 706, 696 cm ⁇ 1 .
  • PTMO (10 g, 10 mmol, degassed) was dissolved in anhydrous DMAc (50 mL).
  • LDI (4.11 g, 20 mmol, distilled) and DBDL catalyst were dissolved in anhydrous DMAc (25 mL) and added dropwise to the PTMO solution, and the reaction was maintained at 70° C. for two hours under N 2 .
  • hydroxyperfluoroacrylate(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11 heptadecafluoro-2-hydroxyundecyl acrylate) (FEO1, 12.058 g, 22 mmol) was dissolved in DMAc (25 mL) with DBDL and added dropwise to the reaction solution. The reactor was kept sealed under N 2 and stirred overnight at room temperature. The product was precipitated in water (2 L) and re-dissolved in diethyl ether (100 mL, 100 ppm BHT), dried with MgSO 4 and filtered. The ether solution was dropped into hexane (400 mL) to precipitate the product and extract un-reacted reagent.
  • PTMO (2.012 g, 2 mmol, degassed) was dissolved in anhydrous DMAc (10 mL).
  • LDI 0.48 g, 4 mmol, distilled
  • DBDL catalyst were dissolved in anhydrous DMAc (5 mL) and was added dropwise to the PTMO solution.
  • the pre-polymer reaction was maintained at 60-70° C. for two hours under N 2 .
  • PTMO (10 g, 10 mmol, degassed) was dissolved in anhydrous DMAc (50 mL).
  • LDI 4.41 g, 20 mmol, distilled
  • DBDL catalyst were dissolved in anhydrous DMAc (22 mL) and was added dropwise to the PTMO solution.
  • the pre-polymer reaction was maintained at 60-70° C. for two hours under N 2 .
  • the hydroxyperfluoroacrylate (3-(perfluoro-3-methylbutyl)-2-hydroxypropyl methacrylate) (FEO3, 9.068 g, 22 mmol) was dissolved in DMAc (23 mL) with DBDL and added dropwise to the pre-polymer solution.
  • the reactor was kept sealed under N 2 and stirred overnight at room temperature.
  • the product was precipitated in water (2 L) and re-dissolved in diethyl ether (100 mL, 100 ppm BHT), dried with MgSO 4 and filtered.
  • the ether solution was dropped into hexane (400 mL) to precipitate the product and extract un-reacted reagent.
  • the hexane was decanted and the solvent extraction procedure was repeated two times.
  • the purified product (Compound 8) was dissolved in diethyl ether (50 mL), and the solvent removed by evaporation in a flow hood at room temperature.
  • PTMO (10.0 g, 10.0 mmol) was weighed into a 250 mL round bottom flask equipped with a stir bar. The flask was heated to 30° C. using an oil bath, and was held under vacuum for 2 hours to remove trace amounts of water. The flask was cooled to room temperature and anhydrous DMAc (50 mL) was added to dissolve the PTMO. LDI (3.18 g, 15.0 mmol), DBDL and anhydrous DMAc (5 mL) were mixed and transferred to the flask via syringe. The reaction flask was heated to 70° C. in an oil bath, and the reaction mixture was stirred for 2 hours.
  • the flask was heated to 45° C. using an oil bath, and under vacuum pumping for 2 hours to remove trace amounts of water.
  • the flask was removed from the oil bath and allowed to cool to room temperature before it was transferred to a glove box with LDI, BAL, a 1 L bottle containing anhydrous DCM solvent and a flame-dry empty 250 mL round bottom flask equipped with a stir bar.
  • the reactor was capped by a rubber septum and removed from the glove box. While the reaction mixture was heated to 65° C. in an oil bath under N 2 , DBDL (0.02 mL) was transferred to the reactor via. a syringe. The reactor was kept stirring at 65° C. overnight (17 hours). The next day, the reaction mixture was cooled to room temperature, and DCM solvent was removed by rotary evaporator to yield a liquid product (Compound 9-ester).
  • PCL diol Polycaprolactone diol (PCL diol) (10 grams, 8 mmol, degassed) was dissolved in anhydrous DMAc (50 mL).
  • LDI 3.39 g, 16 mmol, distilled
  • DBDL catalyst was dissolved in anhydrous DMAc (18 mL) and was added dropwise to the PCL diol solution.
  • the pre-polymer reaction was maintained at 60-70° C. for two hours under N 2 .
  • BAL (7.39 g, 18 mmol) and DBDL were dissolved in anhydrous DMAc (25 mL) and were added dropwise to the pre-polymer solution.
  • the reactor was kept sealed under N 2 and stirred overnight at room temperature.
  • the product (Compound 11-ester) was precipitated in water (3 L), re-suspended in acetone, and purified by passing the acetone solution through SCX SPE columns. The acetone solution was evaporated at 40° C. in a flow oven, and the product was dried under vacuum.
  • PCL diol and Compound 11-ester were dissolved in dioxane and were analyzed by GPC using polystyrene columns and UV detection: the Compound 11-ester chromatogram does not contain un-reacted PCL diol.
  • PCL diol (10 g, 8 mmol, degassed) was dissolved in anhydrous DMAc (50 mL).
  • LDI (3.39 g, 16 mmol, distilled) and DBDL catalyst was dissolved in anhydrous DMAc (17 mL) and was added dropwise to the PCL diol solution.
  • the pre-polymer reaction was maintained at 60-70° C. for two hours under N 2 .
  • FEO1 (9.648 g, 18 mmol) was dissolved in DMAc (24 mL) with DBDL and added dropwise to the pre-polymer solution.
  • the reactor was kept sealed under N 2 and stirred overnight at room temperature.
  • the product was precipitated in water (3 L) and re-dissolved in chloroform (100 mL, 100 ppm BHT), dried with MgSO 4 , centrifuged and the supernatant decanted.
  • the chloroform solution was dropped into hexane (400 mL) to precipitate the product and extract un-reacted reagent.
  • the hexane was decanted and the solvent extraction procedure was repeated twice.
  • the purified product (Compound 12) was dissolved in chloroform (50 mL), and the solvent removed at room temperature in a flow hood.
  • reaction mixture was stirred at 65° C. for 3 hours, and then cooled to room temperature in an ice bath. Then, liquid allyl alcohol (2.70 g, 46.46 mmoL) was introduced into the reactor by syringe injection, and the reaction mixture was kept stirring at room temperature overnight (17 hours). The next day, the reaction mixture was poured into a 1 L beaker containing 900 mL distilled water in order to precipitate the polymer. Removing the wash water yielded a crude liquid product. Repeating the washing twice with distilled water (500 mL) generated a slightly yellow liquid.
  • the 5.92 ppm Based on integration numbers of LDI at 3.17 ppm and allyl at 2.47 ppm, the 5.92 ppm, the amount of allyl groups attached onto the oligomer after the reaction was estimated to be 71%.
  • the absolute number-average molecular weight (Mn) was estimated, using pentafluorobenzene (6.90 ppm) as the external reference against allyl at 5.92 ppm, PTMO at 3.42 ppm and LDI at 3.17 ppm, to be 1099 g/mol.
  • GPC DMF, 1 mL/min, linear PS as standards, UV at 280 nm and RI detector).
  • the estimate conversion of COOH to CO-HEMA is 48% based on 1 H-NMR shift area of 6.12 ppm (HEMA) and 3.14 ppm (LDI).
  • the absolute number-average molecular weight (Mn) was estimated, using pentafluorobenzene (6.90 ppm) as the external reference against octanol at 0.89 ppm, PTMO at 3.42 ppm and LDI at 3.17 ppm, to be 1722 g/mol.
  • GPC analysis the product was dissolved in dioxane and run on a GPC system with a polystyrene column and UV detector: no free monomer was detected.
  • HPLC analysis retention time of 41 minutes (Compound 15), no free monomer detected.
  • the estimate conversion of COOH to CO-allyl alcohol is 38% based on 1 H-NMR shift area of 5.92 ppm (allyl) and 3.15 ppm (LDI).
  • the absolute number-average molecular weight (Mn) was estimated, using pentafluorobenzene (6.90 ppm) as the external reference against octanol at 0.89 ppm, allyl at 5.92 ppm, PTMO at 3.42 ppm and LDI at 3.17 ppm, to be 1576 g/mol.
  • GPC analysis the product was dissolved in dioxane and run on a GPC system with a polystyrene column and UV detector: no free monomer was detected.
  • TGA 2 onset points: (A) 259.1° C., 28.3% mass loss, and (B) 404.9° C., 69.4% mass loss.
  • the C ⁇ C group conversion was monitored on films prepared on KBr discs: C ⁇ C conversion was recorded.
  • TGA 2 onset points: (A) 240.8° C., 34.09% mass loss, (B) 417.5° C., 62.99% mass loss.
  • XPS C: 56.2%, N: 3.80%, O: 14.14%, F: 25.79%.
  • TGA 2 onset points: (A) 288.4° C., 31.4% mass loss, (B) 411.8° C., 67.2% mass loss.
  • XPS C: 58.31%, N: 2.86%, O: 15.97%, F: 21.89%.
  • BPO concentrations (0, 0.05, 0.1, 0.5, and 1 wt % BPO) were evaluated for effectiveness of cure of Compound 2.
  • Compound 2 was dissolved in toluene (0.1 g/mL) prepared with BPO (0, 0.05, 0.1, 0.5, and 1 wt %). 500 ⁇ L of these solutions were cast into 4 mL glass vials, the toluene was evaporated off at room temperature, and the films were cured at 60° C. in an N 2 purged oven. Films prepared with 0, 0.05, and 0.1 wt % BPO content did not cure enough to permit physical manipulation.
  • Films prepared with 0.5 and 1 wt % BPO were analyzed for gel content (acetone extraction): 1 wt % BPO film (100% gel), 0.5 wt % BPO film (58% gel). Equivalent films were also prepared on KBr disks using 25 ⁇ L of the polymer solutions, and these films were analyzed by FTIR. The films prepared with 0-0.1 wt % BPO have signal at 1634 cm ⁇ 1 (C ⁇ C peak), whereas films prepared with 0.5 and 1 wt % BPO have no visible 1634 cm ⁇ 1 signal.
  • V-70 Films of Compound 2 were prepared with 1 wt % V-70 initiator, and were cured in the same manner as the BPO cured film. By DSC analysis, the V-70 was found to be an effective initiator.
  • Shaped articles of Compound 2 were prepared. Compound 2 was dissolved in toluene (0.1 g/mL) containing BPO initiator (1 mg, 1 wt % of Compound 2 mass). The toluene solution was cast into circular and hexagonal molds, and the molds were placed in a semi-enclosed chamber at room temperature for 1 day. The Compound 2 films were then cured for 12 hours in an N 2 purged 60° C. oven. The resulting shaped articles could be removed from the molds, and were elastomeric ( FIG. 3 ).
  • Compound 6 was dissolved in toluene (0.1 g/mL) prepared with BPO (0, 0.05, 0.1, 0.5, and 1 wt %). 1.5 mL of each solution were cast into 24 mL glass vials, the toluene was evaporated off at room temperature, and the films were cured at 60° C. in an N 2 purged oven. All films excepting the 0% BPO film were firm and clear. The film prepared with 0% BPO was soft and tacky. Gel content (acetone extraction): 0 wt % BPO film (completely dissolved), 0.05, 0.1, 0.5 and 1 wt % BPO films (>99% gel).
  • Compound 6 films were prepared using 1 wt % BPO.
  • Compound 6 was dissolved in toluene (0.05 or 0.1 g/mL) containing BPO initiator (1 wt % of Compound 6).
  • the toluene solutions (6 mL) were cast into 4 cm ⁇ 4 cm PTFE wells, and the PTFE casting plates were placed in a casting tank at room temperature for 1 day.
  • the Compound 6 films were cured for 12 hours in an N 2 purged 60° C. oven.
  • the resulting films were clear and elastomeric ( FIG. 4 ).
  • FIG. 5 shows films of cured Compound 6 prepared using the 0.05 and 0.1 g/mL solutions, before and after toluene exposure, indicating no change to film morphology.
  • Contact angle analysis water: 114°
  • porcine plasma 119°
  • porcine blood 116°.
  • XPS analysis (90°): (top surface: C: 56.5%, N: 2.6%, O: 16.4%, F: 23.7%.) (bottom surface: C: 52.6%, N: 2.4%, O: 14.0%, F: 30.3%).
  • Compound 8 was dissolved in toluene (0.1 gram/mL) containing BPO (1 wt % of Compound 8).
  • the toluene solution (6 mL) was cast into 4 cm ⁇ 4 cm PTFE wells, and the PTFE casting plate was placed in a casting tank at room temperature for 1 day.
  • the Compound 8 films were cured for 12 hours in an N 2 purged 60° C. oven.
  • the resulting films were clear, tacky, and elastomeric.
  • Gel extraction analysis 91% gel, 117% swelling.
  • Contact angle analysis advancing angle: 119°.
  • Compound 12 was dissolved in THF (0.1 gram/mL) containing BPO (1 wt % of Compound 12).
  • THF solution (6 mL) was cast into 4 cm ⁇ 4 cm PTFE wells, and the PTFE casting plate was placed in a casting tank at room temperature for 1 day.
  • the Compound 12 films were cured for 12 hours in an N 2 purged 60° C. oven.
  • the resulting films were translucent and elastomeric ( FIG. 6 ).
  • Contact angle analysis advancing angle: 118°.
  • the stainless steel substrates, aluminum weighing pans and KBr disc containing opaque liquid samples were placed in the center of the UV box.
  • the box was purged with argon gas for 10 minutes before the UV lamp was turned on for 5 minutes. All substrates were removed from the box and cooled to room temperature before carrying out film analysis.
  • the UV cure procedure was repeated to samples cast on Teflon molds.
  • Gel content, swell ratio, contact angle measurements, and TGA analysis were performed on films prepared on stainless steel discs. The typical thickness of these films was 0.4 mm.
  • XPS analysis was performed on films cast in aluminum weighing pans.
  • the C ⁇ C group conversion was monitored by FTIR, and performed on films prepared on KBr disc. The average thickness of these latter two films was about 0.03 mm.
  • TGA 2 onset points: (A) 234.9° C., 30.2% mass loss, (B) 407.4° C., 65.5% mass loss.
  • IR The C ⁇ C group conversion was monitored by FTIR and performed on films prepared on KBr discs.
  • SIBS solution (0.5 g/mL in toluene) was cast on stainless steel substrates and an aluminum weighing pan. The toluene was allowed to evaporate at room temperature overnight. In a 20 mL vial, Compound 2, HMP, and MeOH (HPLC grade) were weighed. The vial was vortexed until the components were completely well blended. If air bubbles appeared, the vial was allowed to sit at room temperature until all bubbles dissipated The Compound 2 solution was transferred from the vial to a 50 mL HDPE spraying bottle. The spraying bottle was used to deposit a thin layer of Compound 2 and HMP on top of the SIBS film. MeOH solvent was allowed to evaporate at room temperature for 1 hour under an aluminum foil.
  • EVA solution (0.5 g/mL in toluene) was cast on stainless steel substrates and an aluminum weighing pan. The toluene was allowed to evaporate at room temperature overnight. In a 20 mL vial, Compound 2, HMP, and MeOH (HPLC grade) were weighed. The vial was vortexed until the components were completely well blended. If air bubbles appeared, the vial is allowed to sit at room temperature until all bubbles dissipated. The Compound 2 solution was transferred from the vial to a 50 mL HDPE spraying bottle. The spraying bottle was used to deposit a thin layer of Compound 2 and HMP on top of the EVA film. MeOH solvent was allowed to evaporate at room temperature for 1 hour under an aluminum foil.
  • Compound 2 (0.3 g) was dissolved in toluene (0.1 g/mL) containing BPO (3 mg, 1 wt % of Compound 2 mass).
  • Compound 6 (0.3g) was dissolved in toluene (0.1 g/mL) containing BPO (3 mg, 1 wt % of Compound 6 mass).
  • These two solutions were mixed in a 50:50 ratio, and 6 mL of this combined solution were cast into 4 cm ⁇ 4 cm PTFE wells.
  • the PTFE casting plate was placed in a semi-enclosed chamber at room temperature for 1 day. The film was then cured for 12 hours in an N 2 purged 60° C. oven. The resulting film was clear, elastomeric, and non-tacky ( FIG.
  • Compound 6 (0.3 g) was dissolved in toluene (0.1 g/mL) containing BPO (3 mg, 1 wt % of Compound 6 mass).
  • Compound 8 (0.3g) was dissolved in toluene (0.1 g/mL) containing BPO (3 mg, 1 wt % of Compound 8 mass). These two solutions were mixed in a 50:50 ratio, and 6 mL of this combined solution were cast into 4 cm ⁇ 4 cm PTFE wells. The PTFE casting plate was placed in a semi-enclosed chamber at room temperature for 1 day. The film was then cured for 12 hours in an N 2 purged 60° C. oven.
  • Compound 6 (0.3 g) was dissolved in toluene (0.1 g/mL) containing BPO (3 mg, 1 wt % of Compound 6 mass).
  • FEO1 (0.3 g) was dissolved in toluene (0.1 g/mL) containing BPO (3 mg, 1 wt % of FEO1 mass).
  • These two solutions were mixed in a 50:50 ratio, and 6 mL of this combined solution were cast into 4 cm ⁇ 4 cm PTFE wells.
  • the PTFE casting plate was placed in a semi-enclosed chamber at room temperature for 1 day. The film was then cured for 12 hours in an N 2 purged 60° C. oven.
  • Compound 2 (0.1 g) was dissolved in toluene (0.1 g/mL) containing BPO (1 mg, 1 wt % of Compound 2 mass).
  • Compound 1-ester (0.1 g) was dissolved in toluene (0.1 g/mL) containing BPO (1 mg, 1 wt % of Compound 1-ester mass). These two solutions were mixed in a 50:50 ratio, and 2 mL of this combined solution were cast into 2 cm ⁇ 2 cm PTFE wells. The PTFE casting plate was placed in a semi-enclosed chamber at room temperature for 1 day. The film was then cured for 12 hours in an N 2 purged 60° C. oven. The resulting cured material was homogeneous and firm.
  • Gel extraction analysis (acetone): 87% gel.
  • XPS analysis (90°): top surface: C: 41.4%, N: 1.1%, O: 9.9%, F: 45.4%.
  • HEMA (0.6 g) was dissolved in toluene (6 mL, 0.1 g/mL) containing BPO (6 mg, 1 wt % of HEMA mass), and this solution was cast into a 4 cm ⁇ 4 cm PTFE well.
  • the PTFE casting plate was placed in a semi-enclosed chamber at room temperature for 1 day. The film was then cured for 12 hours in an N 2 purged 60° C. oven. The resulting cured material was hard and inconsistent in thickness.
  • FEO1 (0.6 g) was dissolved in toluene (6 mL, 0.1 g/mL) containing BPO (6 mg, 1 wt % of FEO1 mass), and this solution was cast into a 4 cm ⁇ 4 cm PTFE well.
  • the PTFE casting plate was placed in a semi-enclosed chamber at room temperature for 1 day. The film was then cured for 12 hours in an N 2 purged 60° C. oven. The resulting cured material was hard and inconsistent in thickness.
  • Compound 2 (200 mg) was dissolved in toluene (4 mL, 0.05 g/mL), stirred for 90 minutes at room temperature and BPO (2 mg, 1 wt % of Compound 2 mass) was added and the mixture was stirred for an additional 30 minutes.
  • the solution blend was sprayed onto stents using an EFD spray system, and the coatings were cured at 60° C. in an N 2 purged oven for 12 hours. SEM analysis ( FIG. 11 ) indicated that the stents were uniformly coated.
  • a Compound 2 coated stent was crimped on a balloon and deployed at 10 psi. Coating remained intact ( FIG. 12 ).
  • Compound 8 (200mg) was dissolved in toluene (4 mL, 0.05 g/mL), stirred for 90 minutes at room temperature and BPO (2 mg, 1 wt % of Compound 8 mass) was added and the mixture was stirred for an additional 30 minutes.
  • the solution blend was sprayed onto stents using an EFD spray system, and the coatings were cured at 60° C. in an N 2 purged oven for 12 hours. SEM analysis ( FIG. 16 ) indicated that the stents were uniformly coated.
  • Compound 12 (200 mg) was dissolved in toluene (4 mL, 0.05 g/mL), stirred for 90 minutes at room temperature and BPO (2 mg, 1 wt % of Compound 12 mass) was added and the mixture was stirred for an additional 30 minutes.
  • the solution blend was sprayed onto stents using an EFD spray system, and the coatings were cured at 60° C. in an N 2 purged oven for 12 hours. SEM analysis ( FIG. 17 ) indicated that the stents showed decent coating.
  • Compound 12 (200 mg) was dissolved in 75:25 toluene:THF (4 mL, 0.05 g/mL), stirred for 90 minutes at room temperature and BPO (2 mg, 1 wt % of Compound 12 mass) was added and the mixture was stirred for an additional 30 minutes.
  • the solution blend was sprayed onto stents using an EFD spray system, and the coatings were cured at 60° C. in an N 2 purged oven for 12 hours. SEM analysis ( FIG. 18 ) indicated that the stents were uniformly coated.
  • Compound 6 and Compound 8 (1:1, total 200 mg) were dissolved in toluene (4 mL, 0.05 g/mL), stirred for 90 minutes at room temperature and BPO (2 mg, 1 wt % of Compound 6 and Compound 8 combined mass) was added and the mixture was stirred for an additional 30 minutes.
  • the solution blend was sprayed onto stents using an EFF spray system, and the coatings were cured at 60° C. in an N 2 purged oven for 12 hours. SEM analysis ( FIG. 20 ) indicated that the stents were uniformly coated.
  • Compound 6 (200 mg) was dissolved in 75:25 toluene:THF (4 mL, 0.05 g/mL), stirred for 90 minutes at room temperature and Paclitaxel (17.6 mg, 8.8wt % of Compound 6 mass) and BPO (2 mg, 1 wt % of Compound 6 mass) was added and the mixture was stirred for an additional 30 minutes.
  • the solution blend was sprayed onto stents using an EFD spray system, and the coatings were cured at 60° C. in an N 2 purged oven for 12 hours. SEM analysis ( FIG. 21 ) indicated that the stents were uniformly coated.
  • Example 19 Samples of film from Example 19 (1 cm ⁇ 2 cm) were weighed and incubated in MEM media for 24 hours. A counted aliquot of L-929 mouse fibroblast culture was seeded into each MEM extract, and stability of the cell population was evaluated after 24 hours using a trypan blue exclusion method. By this cytotoxicity evaluation method, the Compound 2 films were non-toxic.
  • Compound 2 was dissolved in toluene (0.1 g/mL) containing BPO initiator (1 wt % of Compound 2 mass).
  • the toluene solution was cast into 96 well polypropylene plates (6 wells per plate), and the plates were placed in a semi-enclosed chamber at room temperature for 1 day.
  • the Compound 2 films were then cured for 12 hours in an N 2 purged 60° C. oven, and vacuum dried.
  • films of SIBS were cast in a second 96 well plate: a 0.1 g/mL toluene solution of SIBS was cast in 6 wells, the plates were placed in a semi-enclosed chamber at room temperature for 1 day, dried in a 60° C.
  • Example 20 Samples of film from Example 20 (1 cm ⁇ 2 cm) were weighed and incubated in MEM media for 24 hours. A counted aliquot of L-929 mouse fibroblast culture was seeded into each MEM extract, and stability of the cell population was evaluated after 24 hours using a trypan blue exclusion method. By this cytotoxicity evaluation method, the Compound 6 films were non-toxic.
  • Compound 6 was dissolved in toluene (0.1 g/mL) containing BPO initiator (1 wt % of Compound 6 mass).
  • the toluene solution was cast into 96 well polypropylene plates (6 wells per plate), and the plates were placed in a semi-enclosed chamber at room temperature for 1 day.
  • the Compound 6 films were then cured for 12 hours in an N 2 purged 60° C. oven, and vacuum dried.
  • films of SIBS were cast in a second 96 well plate: a 0.1 g/mL toluene solution of SIBS was cast in 6 wells, the plates were placed in a semi-enclosed chamber at room temperature for 1 day, dried in a 60° C.
  • Compound 12 was dissolved in toluene (0.1 g/mL) containing BPO initiator (1 wt % of Compound 12 mass).
  • the toluene solution was cast into 96 well polypropylene plates (6 wells), and the plates were placed in a semi-enclosed chamber at room temperature for 1 day.
  • the Compound 12 films were then cured for 12 hours in an N 2 purged 60° C. oven, and vacuum dried.
  • films of SIBS were cast in a second 96 well plate: a 0.1 g/mL toluene solution of SIBS was cast in 6 wells, the plates were placed in a semi-enclosed chamber at room temperature for 1 day, dried in a 60° C. oven for 1 day, and vacuum dried.
  • Compounds from Section 1 provide a polymeric platform with functional groups suitable for the immobilization and inclusion of active agents.
  • Compounds 6, 7, and 8 have functional groups for covalent interaction with active agents.
  • Films or stent coatings including active agents are prepared according to Section 2 and 3 methods.
  • TGA 2 onset points: (A) 234.9° C., 30.2% mass loss, (B) 407.4° C., 65.5% mass loss.
  • IR the C ⁇ C group conversion is monitored by FTIR and performed on films prepared on KBr discs.
  • XPS C: 50.68%, N: 3.02%, O: 12.00%, F: 34.31%. Aspirin release was examined for films cast in Teflon molds ( FIG. 22 ).
  • Ibuprofen was mixed with Compound 2 (25 wt % of total mass) in toluene (0.1 gram/mL) containing BPO (1 wt %), and cured at 60° C. under N 2 .
  • the release of ibuprofen from the cured film was measured over 96 hours in PBS solution at 37° C. by UV spectrophotometer measurement ( FIG. 24 ).
  • N-trityl ciprofloxacin, EDC, and DMAP (in a stoichiometory of 1:8:0.5 molar ratio) were dissolved in anhydrous DCM. 10% excess HEMA relative to the mole of COOH groups was then added into the reaction system. The reaction mixture was stirred at room temperature under N 2 for 7 days. After rotary evaporated the solvent, the solid residual was extracted by diethyl ether at room temperature. The crude product of this reaction was roughly dried and then was dissolved in DCM. TFAc (10 vol % of DCM) was added in the solution, stirred at room temperature for 14 hours. The solvent was removed by rotary evaporation at room temperature. The solid crude product was stirred in diethyl ether and filtered three times.
  • Hydrocortisone (2.5 g, 6.90 mmol) was transferred to a flame-dried 250 mL reaction flask equipped with a stir bar. The flask was capped by a rubber septum and filled with N 2 provided by a balloon. Anhydrous DCM (100 mL) was transferred to the flask via a syringe. Hydrocortisone did not dissolve in DCM completely, forming a milky suspension. TEA (1.10 ml, 7.89 mmol) was transferred to the reaction flask by a syringe.
  • Hydrocortisone was mixed with Compound 6 (1 wt % of total mass) in toluene (0.1 gram/mL) containing initiator (1 wt %), and cured at 60° C. under N 2 .
  • the release of hydrocortisone from the cured film was measured over 24 hours in PBS solution at 37° C. by HPLC measurement ( FIG. 25 ).
  • a stent was coated using the same casting solution and cure method ( FIG. 26 ).
  • Dexamethasone was mixed with Compound 6 (1 wt % of total mass) in toluene (0.1 gram/mL) containing initiator (1 wt %), and cured at 60° C. under N 2 .
  • the release of dexamethasone from the cured film was measured over 24 hours in PBS solution at 37° C. by HPLC measurement ( FIG. 25 ).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Materials For Medical Uses (AREA)
US12/681,757 2007-10-05 2008-10-02 Oligofluorinated cross-linked polymers and uses thereof Pending US20110091508A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/681,757 US20110091508A1 (en) 2007-10-05 2008-10-02 Oligofluorinated cross-linked polymers and uses thereof
US15/373,138 US10039864B2 (en) 2007-10-05 2016-12-08 Oligofluorinated cross-linked polymers and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99792907P 2007-10-05 2007-10-05
PCT/CA2008/001761 WO2009043174A1 (en) 2007-10-05 2008-10-02 Oligofluorinated cross-linked polymers and uses thereof
US12/681,757 US20110091508A1 (en) 2007-10-05 2008-10-02 Oligofluorinated cross-linked polymers and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2008/001761 A-371-Of-International WO2009043174A1 (en) 2007-10-05 2008-10-02 Oligofluorinated cross-linked polymers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/373,138 Continuation US10039864B2 (en) 2007-10-05 2016-12-08 Oligofluorinated cross-linked polymers and uses thereof

Publications (1)

Publication Number Publication Date
US20110091508A1 true US20110091508A1 (en) 2011-04-21

Family

ID=40525811

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/681,757 Pending US20110091508A1 (en) 2007-10-05 2008-10-02 Oligofluorinated cross-linked polymers and uses thereof
US15/373,138 Active US10039864B2 (en) 2007-10-05 2016-12-08 Oligofluorinated cross-linked polymers and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/373,138 Active US10039864B2 (en) 2007-10-05 2016-12-08 Oligofluorinated cross-linked polymers and uses thereof

Country Status (5)

Country Link
US (2) US20110091508A1 (ja)
EP (1) EP2203498B1 (ja)
JP (1) JP5599712B2 (ja)
CA (1) CA2701186C (ja)
WO (1) WO2009043174A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170002140A1 (en) * 2014-02-03 2017-01-05 Manac Inc. Bromine-containing polyether polymers and methods for producing the same
CN107244730A (zh) * 2017-07-19 2017-10-13 广东水道元环保科技有限公司 基于物联网的双环交叉球型生物活性填料构件
US10195311B2 (en) 2009-12-18 2019-02-05 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11318232B2 (en) 2018-05-22 2022-05-03 Interface Biologics, Inc. Compositions and methods for delivering drugs to a vessel wall
CN115300672A (zh) * 2017-05-30 2022-11-08 赢创加拿大公司 具有改性表面的血管移植物
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11581487B2 (en) 2017-04-26 2023-02-14 Oti Lumionics Inc. Patterned conductive coating for surface of an opto-electronic device
US11985841B2 (en) 2020-12-07 2024-05-14 Oti Lumionics Inc. Patterning a conductive deposited layer using a nucleation inhibiting coating and an underlying metallic coating

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032005T2 (en) 2009-05-15 2017-08-28 Interface Biologics Inc Antithrombotic hollow fiber membranes, embedded resin and blood tube
US10772992B2 (en) 2016-02-17 2020-09-15 The Governing Council Of The University Of Toronto Soft tissue filler
JP7254704B2 (ja) 2016-10-18 2023-04-10 エボニック カナダ インコーポレーテッド 表面修飾マクロ分子を含む可塑化ｐｖｃ混合物及びそれから製造された物品
DE102017111486A1 (de) * 2017-05-17 2018-11-22 Phenox Gmbh Beschichtung für Medizinprodukte
US20200188096A1 (en) * 2017-05-30 2020-06-18 Evonik Canada Inc. Prosthetic valves having a modified surface
CN109957322B (zh) * 2019-04-01 2021-08-27 江南大学 一种双交联固化防雾薄膜及其制备方法
CN116285637B (zh) * 2023-04-10 2024-01-16 齐鲁工业大学(山东省科学院) 高强度防腐水性聚氨酯、防腐材料及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031547A1 (en) * 1995-04-04 1996-10-10 Novartis Ag Polymerizable perfluoroalkylether siloxane macromer
JPH11171929A (ja) * 1997-12-15 1999-06-29 Toray Ind Inc プラスチック成形品
US20030097120A1 (en) * 2001-06-07 2003-05-22 Santerre Paul J. Bioactive surface modifiers for polymers and articles made therefrom
US20030171804A1 (en) * 1997-06-24 2003-09-11 Werner Krause Stents coated with fluoroalkyl groups

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
IT1187705B (it) * 1985-07-24 1987-12-23 Montefluos Spa Polimeri fluorurati e resine da essi derivate
US5021602A (en) * 1989-06-09 1991-06-04 The Dow Chemical Company Reactive compounds containing perfluorocyclobutane rings
US5037919A (en) * 1989-06-09 1991-08-06 The Dow Chemical Company Reactive compounds containing perfluorovinyl groups
JPH04332760A (ja) * 1991-05-09 1992-11-19 Nippon Contact Lens Kk 医療用材料
IT1250739B (it) * 1991-08-02 1995-04-21 Ausimont Spa Impiego di poliuretani fluorurati per il trattamento di film o fogli di cellulosa, mica, caolino e simili materiali naturali
JPH05255496A (ja) * 1992-01-18 1993-10-05 Sumitomo Electric Ind Ltd 含フッ素ポリエーテルジ（メタ）アクリレートおよび光硬化性組成物
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
AUPN215995A0 (en) * 1995-04-04 1995-04-27 Ciba-Geigy Ag Novel materials
NZ313583A (en) * 1995-08-03 1999-01-28 Paul J Santerre Fluoroligomer surface modifiers for polymers
JPH09281346A (ja) * 1996-04-16 1997-10-31 Sumitomo Electric Ind Ltd プラスチッククラッド光ファイバ
AU7487998A (en) 1997-05-14 1998-12-08 Minnesota Mining And Manufacturing Company Fluorochemical composition comprising a polyurethane having a fluorochemical oligomer and a hydrophilic segment to impart stain release properties to a substrate
US6573971B1 (en) 1999-02-05 2003-06-03 Varintelligent (Bvi) Limited Bistable twisted nematic LCD without an initial twist angle of 180 degrees and not a multiple of 90 degrees
EP1171490A1 (en) * 1999-03-31 2002-01-16 Universiteit Gent Fluorinated copolymers for coating biomedical devices and a process for their manufacture
JP4782934B2 (ja) * 2000-09-27 2011-09-28 日本化薬株式会社 低屈折率樹脂組成物およびその硬化物
CA2425753C (en) * 2000-09-29 2014-08-05 Ethicon, Inc. An implantable medical device having a biocompatible film applied to as urface thereof
US20040043067A1 (en) 2002-06-19 2004-03-04 Salamone Joseph C. Fluorosiloxane matrix controlled diffusion drug delivery systems
EP1868664A2 (en) * 2005-04-15 2007-12-26 Interface Biologics Inc. Methods and compositions for the delivery of biologically active agents
WO2009049426A1 (en) 2007-10-19 2009-04-23 Interface Biologics Inc. Self-eliminating coatings
JP2013514278A (ja) 2009-12-18 2013-04-25 インターフェース バイオロジクス，インコーポレーテッド 自己集合コーティングからの薬物の局所送達

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031547A1 (en) * 1995-04-04 1996-10-10 Novartis Ag Polymerizable perfluoroalkylether siloxane macromer
US20030171804A1 (en) * 1997-06-24 2003-09-11 Werner Krause Stents coated with fluoroalkyl groups
JPH11171929A (ja) * 1997-12-15 1999-06-29 Toray Ind Inc プラスチック成形品
US20030097120A1 (en) * 2001-06-07 2003-05-22 Santerre Paul J. Bioactive surface modifiers for polymers and articles made therefrom

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Muh et al. (Biomaterials 23 (2002) 2849-2854), and Santerre (Pub. No.: US 2003/0097120; Pub. Date: May 22, 2003). *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195311B2 (en) 2009-12-18 2019-02-05 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
US20170002140A1 (en) * 2014-02-03 2017-01-05 Manac Inc. Bromine-containing polyether polymers and methods for producing the same
US9879116B2 (en) * 2014-02-03 2018-01-30 Manac Inc. Bromine-containing polyether polymers and methods for producing the same
US11581487B2 (en) 2017-04-26 2023-02-14 Oti Lumionics Inc. Patterned conductive coating for surface of an opto-electronic device
CN115300672A (zh) * 2017-05-30 2022-11-08 赢创加拿大公司 具有改性表面的血管移植物
CN107244730A (zh) * 2017-07-19 2017-10-13 广东水道元环保科技有限公司 基于物联网的双环交叉球型生物活性填料构件
US11447510B2 (en) 2017-10-09 2022-09-20 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11851451B2 (en) 2017-10-09 2023-12-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11180517B2 (en) 2017-10-09 2021-11-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10954259B1 (en) 2017-10-09 2021-03-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10947257B2 (en) 2017-10-09 2021-03-16 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11505564B2 (en) 2017-10-09 2022-11-22 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11149044B2 (en) 2017-10-09 2021-10-19 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11629159B2 (en) 2017-10-09 2023-04-18 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11939346B2 (en) 2017-10-09 2024-03-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11318232B2 (en) 2018-05-22 2022-05-03 Interface Biologics, Inc. Compositions and methods for delivering drugs to a vessel wall
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11865126B2 (en) 2019-04-17 2024-01-09 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11738035B2 (en) 2019-04-17 2023-08-29 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11985841B2 (en) 2020-12-07 2024-05-14 Oti Lumionics Inc. Patterning a conductive deposited layer using a nucleation inhibiting coating and an underlying metallic coating

Also Published As

Publication number Publication date
JP2011502182A (ja) 2011-01-20
WO2009043174A1 (en) 2009-04-09
CA2701186A1 (en) 2009-04-09
JP5599712B2 (ja) 2014-10-01
US10039864B2 (en) 2018-08-07
CA2701186C (en) 2017-09-19
US20170340781A1 (en) 2017-11-30
EP2203498B1 (en) 2017-12-06
EP2203498A1 (en) 2010-07-07
EP2203498A4 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
US10039864B2 (en) Oligofluorinated cross-linked polymers and uses thereof
US8445016B2 (en) Grafted polymers and uses thereof
US20220040385A1 (en) Local delivery of drugs from self assembled coatings
US8574604B2 (en) Methods and compositions for the delivery of biologically active agents
US8440176B2 (en) Covalently grafted pharmaceutically active polymers
US20220047773A1 (en) Self-eliminating coatings
Zhang et al. Surface functionalization of polyurethanes: A critical review

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING RESPONSE FOR INFORMALITY, FEE DEFICIENCY OR CRF ACTION